TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00482664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: Tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-866,087
Description: Tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study: NCT01756651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin
Description: comparison of Intranasal fentanyl 100mcg vs 200 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin
Description: comparison of Intranasal fentanyl 100mcg vs 200 mcg.
Study: NCT02316574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Coping Skills Therapy
Description: Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use.
Study: NCT03081962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bundle
Description: Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
Study: NCT01946750

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Saliva
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole blood
Description: Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
Study: NCT04628429

Intervention type: DRUG
Intervention: Erenumab
Description: anti-CGRP-receptor monoclonal anti-body

Intervention type: DRUG
Intervention: Galcanezumab
Description: anti-CGRP-ligand monoclonal anti-body

Intervention type: DRUG
Intervention: Galcanezumab
Description: anti-CGRP-ligand monoclonal anti-body

Intervention type: DRUG
Intervention: Fremanezumab
Description: anti-CGRP-ligand monoclonal anti-body

Intervention type: DRUG
Intervention: Fremanezumab
Description: anti-CGRP-ligand monoclonal anti-body
Study: NCT00932906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different self-training methods
Description: Self training with MiniAnne Training Kit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard training
Description: Instructor-based training meeting ERC directions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard training
Description: Instructor-based training meeting ERC directions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard training
Description: Instructor-based training meeting ERC directions
Study: NCT04062591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam group
Description: patients will receive 0.4 mg/kg piroxicam IM

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: saline IM in the same dose of piroxicam
Study: NCT03738618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 15 μg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 μg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 μg, and the maximum daily dose was 24 μg.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049.~Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.
Study: NCT02722200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
Study: NCT04295239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Pre and Post operative MRI
Study: NCT00640848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 400 mg in two treatment sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 200 mg in two treatment sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 100 mg in two treatment sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 50 mg mg in two treatment sequences

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almorexant
Description: 1 dose of 1000 mg in two treatment sequences
Study: NCT00771888

Intervention type: DRUG
Group type: OTHER
Intervention: lanreotide
Description: lanreotide
Study: NCT03605446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuit acceptance
Description: Acceptance of high protein biscuits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuit acceptance
Description: Acceptance of high protein biscuits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuit acceptance
Description: Acceptance of high protein biscuits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuit acceptance
Description: Acceptance of high protein biscuits

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Biscuit acceptance
Description: Acceptance of high protein biscuits
Study: NCT04566601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT02333799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: 100mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Scored 600mg tablets
Study: NCT04160858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week \& 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Wait-list control
Study: NCT02039284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SES
Description: SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT
Description: The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRCIT
Description: VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation program
Description: The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
Study: NCT03499314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active RS-tDCS +At-Home Manual Dexterity Training
Description: Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham RS-tDCS +At-Home Manual Dexterity Training
Description: Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual dexterity training
Description: Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual dexterity training
Description: Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
Study: NCT02583295

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music sound
Description: The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maternal sound
Description: The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
Study: NCT01867502

Intervention type: DRUG
Group type: OTHER
Intervention: MET + Vildagliptin Group
Description: Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator.

Intervention type: DRUG
Group type: OTHER
Intervention: MET + Glibenclamide Group
Description: The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator.
Study: NCT02466984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide intravenous
Description: Administration route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoclopramide intravenous
Description: Administration route
Study: NCT05062135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 400 Mg Vaginal Suppository on PCOS
Description: The same drug will be used in control group
Study: NCT03295760

Intervention type: DRUG
Intervention: Q10 Coenzyme
Study: NCT00931606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: up to 4 subcutaneous doses of sotatercept given once every 28 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: up to 4 subcutaneous doses of sotatercept given once every 28 days
Study: NCT00004918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02657811

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miri, Benchtop Multi-room incubator
Description: Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miri TL, Time-Lapse incubator
Description: Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Miri TL, Time-Lapse incubator
Description: Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
Study: NCT04369248

Intervention type: OTHER
Intervention: hepassocin
Description: hepassocin levels in polycystic ovary syndrome

Intervention type: OTHER
Intervention: hepassocin
Description: hepassocin levels in polycystic ovary syndrome

Intervention type: OTHER
Intervention: hepassocin
Description: hepassocin levels in polycystic ovary syndrome
Study: NCT03325907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigational template
Description: The navigational template was created based on computed tomography data using three-dimensional technology.
Study: NCT01703637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: * before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: * before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~* before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: * before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~* before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy
Study: NCT03484858

Intervention type: OTHER
Group type: OTHER
Intervention: High glycaemic index meal and exercise

Intervention type: OTHER
Group type: OTHER
Intervention: High glycaemic index meal and rest

Intervention type: OTHER
Group type: OTHER
Intervention: Low glycaemic index meal and exercise
Study: NCT02045771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Support Group
Description: In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
Study: NCT03492697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Immediate Release Tablet
Description: Immediate Release Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Controlled Release Tablet (long)
Description: Controlled Release tablet (long)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Controlled Release Tablet (short)
Description: Controlled Release tablet (short)
Study: NCT03484858

Intervention type: OTHER
Group type: OTHER
Intervention: Low glycaemic index meal and rest
Study: NCT01716442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02147132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Nasal Spray
Description: 7 days. 1 mg/dose, up to 40x/day.
Study: NCT03492697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 Immediate Release Solution
Description: PF-06882961 Immediate Release solution
Study: NCT03735862

Intervention type: BIOLOGICAL
Intervention: Hepatic derived surgical matrix
Description: Hiatal hernia repair with MIROMESH
Study: NCT01524770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered by subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered by subcutaneous (SC) injection
Study: NCT02322554

Intervention type: BIOLOGICAL
Intervention: Cellular and tissue based products
Description: Procedure: Application of device or biological to wounds
Study: NCT02214277

Intervention type: DEVICE
Group type: OTHER
Intervention: Cerebral Protection System-The SENTINEL System with TAVR
Description: Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Protection System-The SENTINEL System with TAVR
Description: Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR